A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Advanced or Metastatic Solid TumorsCancerSolid Cancers
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Semafore Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00907205
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Scottsdale Clinical Research Institute, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath